NEURONETICS INC
STIMNASDAQTrading Snapshot
- Day Range
- $2.34 – $2.39
- 52-Week Range
- $0.80 – $3.44
- Volume
- $3.69B
- Avg Volume
- $3.56B
- Shares Outstanding
- 69.6M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $149M
- Last Q Revenue
- $42M
- P/E Ratio
- -5.5
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-0.43
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +87.5%
Why Investors Own STIM
- ✓High-growth profile — revenue up +46.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEURONETICS INC
STIM
StockOtter · stockotter.spaceAbout NEURONETICS INC
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
Neuronetics Q2 Earnings Call Highlights
Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial p
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
Neuronetics and Jorey Chernett Announce Shared Vision
MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of Pointillist Family Off
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo